Menu Search
Equities

Standard BioTools Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FLB:BRN

Standard BioTools Inc

Actions
  • Price (CHF)0.869
  • Today's Change0.00 / 0.00%
  • Shares traded325.00
  • 1 Year change--
  • Beta1.3370
Data delayed at least 15 minutes, as of Jun 12 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

  • Revenue in USD (TTM)128.83m
  • Net income in USD-109.46m
  • Incorporated2007
  • Employees818.00
  • Location
    Standard BioTools Inc50 MILK STREET, 10TH FLOORBOSTON 02109United StatesUSA
  • Phone+1 (650) 266-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.standardbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.